IMPACT, NCT00806234: Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics |
|
|
| Completed | 4 | 127 | US | Aripiprazole or Perphenazine, Abilify, Trilafon, Metformin, Glucophage, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine, Zyprexa, Seroquel, Risperdal, Geodon, Abilify, Saphris, Sycrest, Fanapt, Fanapta, Zomaril, Latuda, Invega, Symbyax | Johns Hopkins University, National Institute of Mental Health (NIMH), University of Maryland, University of North Carolina, Chapel Hill, The Zucker Hillside Hospital | Psychotic Disorders | 03/14 | 03/14 | | |
NCT01932541: Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old |
|
|
| Withdrawn | 4 | 0 | US | Latuda (Lurasidone), Lurasidone, Latuda | Massachusetts General Hospital | Mania, Bipolar I, Bipolar II, Bipolar Spectrum Disorder, Bipolar Disorder | 07/18 | 07/18 | | |
